<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="867">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149872</url>
  </required_header>
  <id_info>
    <org_study_id>P21.083</org_study_id>
    <nct_id>NCT05149872</nct_id>
  </id_info>
  <brief_title>The Breath-2 Trial</brief_title>
  <official_title>Recovery of Carotid Body Function After Full Recovery Neuromuscular Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, cross over, experimental trial in which carotid body function will be&#xD;
      evaluated in 35 healthy subjects during partial muscle relaxation and after recovery from&#xD;
      muscle relaxation&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid body function after full recovery of neuromuscular block</measure>
    <time_frame>40 minutes after full recovery of neuromuscular block</time_frame>
    <description>Carotid body function will be determined by measuring acute hypoxic ventilatory response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid body function at partial neuromuscular block TOF ratio 0.7</measure>
    <time_frame>5 minutes after stable partial neuromuscular block</time_frame>
    <description>Carotid body function will be determined by measuring acute hypoxic ventilatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid body function at partial neuromuscular block TOF ratio 0.9</measure>
    <time_frame>5 minutes after stable partial neuromuscular block</time_frame>
    <description>Carotid body function will be determined by measuring acute hypoxic ventilatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid body function at full recovery TOF ratio 1.0</measure>
    <time_frame>0 minutes after full recovery of neuromuscular block</time_frame>
    <description>Carotid body function will be determined by measuring acute hypoxic ventilatory response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid body function after full recovery of neuromuscular block</measure>
    <time_frame>20 minutes after full recovery of neuromuscular block</time_frame>
    <description>Carotid body function will be determined by measuring acute hypoxic ventilatory response</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Peripheral Chemosensitivity</condition>
  <arm_group>
    <arm_group_label>TOF ratio 0.9 spontaneous recovery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TOF ratio maintained at 0.9, spontaneous recovery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOF ratio 0.7 spontaneous recovery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TOF ratio maintained at 0.7, spontaneous recovery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOF ratio 0.7 low dose sugammadex</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TOF ratio maintained at 0.7, reversal with sugammadex 2 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOF ratio 0.7 high dose sugammadex</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TOF ratio maintained at 0.7, reversal with sugammadex 4 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Muscle relaxation</intervention_name>
    <description>Rocuronium will be used to induce partial paralysis</description>
    <arm_group_label>TOF ratio 0.7 high dose sugammadex</arm_group_label>
    <arm_group_label>TOF ratio 0.7 low dose sugammadex</arm_group_label>
    <arm_group_label>TOF ratio 0.7 spontaneous recovery</arm_group_label>
    <arm_group_label>TOF ratio 0.9 spontaneous recovery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reversal</intervention_name>
    <description>Sugamamdex will be used to reverse muscle relaxation</description>
    <arm_group_label>TOF ratio 0.7 high dose sugammadex</arm_group_label>
    <arm_group_label>TOF ratio 0.7 low dose sugammadex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        * age &gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI index &gt; 30 kg/m2&#xD;
&#xD;
          -  Known or suspected neuromuscular disorders impairing neuromuscular function;&#xD;
&#xD;
          -  Allergies to muscle relaxants, anesthetics or narcotics;&#xD;
&#xD;
          -  A (family) history of malignant hyperthermia or any other muscle disease;&#xD;
&#xD;
          -  Any neurological or psychiatric illness (including a history of anxiety).&#xD;
&#xD;
          -  ASA class 3 or higher&#xD;
&#xD;
          -  Gastro-oesophageal regurgitation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Leiden Medical University</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2333ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Dahan, MD, PhD, Professor</last_name>
      <phone>+31715262301</phone>
      <email>a.dahan@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Albert Dahan, MD, PhD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>Albert Dahan</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

